StockData

Incyte vs Medpace

INCY and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INCY and MEDP compare

Incyte is the larger company, worth 1.3 times as much as Medpace ($24.3B against $18.3B).

On earnings, Medpace is cheaper: it trades at 36.2× trailing earnings, against 63.3× for Incyte.

Incyte grew revenue faster over the last twelve months (24.9% versus 20.4% for Medpace).

Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with 6.7% at Incyte.

Medpace scores higher on the StockData Score (14 against 13 for Incyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINCYMEDP
Size and price
Market cap$24.3B$18.3B
Share price$119.09$653.09
Change, 1 year14.3%10.7%
Change, 5 years74.2%211%
Beta (5Y)0.200.33
Employees2,8446,200
StockData Score
Total score1314 (better)
Valuation score00
Growth score44
Performance score35 (better)
Health score6 (better)5
Dividend score00
Valuation
P/E63.3×36.2× (better)
P/S4.0× (better)6.4×
P/B4.3× (better)31.2×
EV/EBITDA29.0×28.9× (better)
P/FCF–27.4×
PEG1.03 (better)1.29
FCF yield–3.7%
Fair value$62.34$459.97
Margin of safety−91.0%−42.0% (better)
Growth
Revenue growth (TTM)24.9% (better)20.4%
Revenue growth, 5Y average14.0%22.3% (better)
Net income growth (TTM)−66.1%19.6% (better)
EPS growth (TTM)−68.2%26.1% (better)
EPS growth, 5Y average–31.8%
Profitability
Gross margin92.7%–
Operating margin10.4%21.4% (better)
Net margin6.7%18.2% (better)
FCF margin–23.5%
Return on equity7.8%118% (better)
Return on invested capital13.9%–
Financial health
Debt / equity0.000.00
Interest coverage268×–
Current ratio3.84 (better)0.83
Altman Z-score10.70 (better)8.13
Piotroski F-score8 (better)6
Dividends and buybacks
Buyback yield–1.6%
Shareholder yield0.00%1.6% (better)
Ownership
Held by institutions99.4%88.3%
Held by insiders33.2%20.0%
Insider net buying, 12 months−$66.0M (better)−$262M
Superinvestors holding–2
Short interest, % of float7.8%6.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.